An overview of Chugai, including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo

blonca9
Nov 14, 2024
1 min read

Dr. Okuda describes Chugai’s vision to be a Top Innovator in 2030, the science that the company excels in, including unique midsize molecules, program highlights in areas such as oncology, hemophilia, and obesity, Japan’s biotech ecosystem, and more.

Recent Posts

See All

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

An overview of Chugai, including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight